DiaSorin Enters U.S. Molecular and Immunoassay Market
By LabMedica International staff writers Posted on 26 May 2016 |
DiaSorin (Saluggia, Italy) and Quest Diagnostics (Madison, NJ, USA) have announced an agreement under which DiaSorin will buy the Focus Diagnostics (Cypress, CA, UYA) immunodiagnostic and molecular diagnostic products business.
As a result of the acquisition, DiaSorin will have access to Focus' product lines, including the Simplexa molecular line, the HerpeSelect HSV serology line, and the DxSelect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) assays. This will significantly increase its presence in the growing market of infectious disease molecular testing. DiaSorin will also strengthen its offering in the U.S. market by gaining access to approximately 200 hospitals served today by Focus.
Gaining access to the current Focus customer base in the United States, which consists mainly of large hospitals, will also allow DiaSorin to speed up U.S. market penetration of its LIAISON Immunoassay platform. The company will also leverage its commercial presence worldwide to distribute Focus products in markets in Europe and Asia. Under the terms of the agreement, DiaSorin will pay to Quest Diagnostics USD 300 million in cash for all the tangible and intangible assets of Focus used to develop, manufacture, and distribute its molecular diagnostic products and its traditional immunoassay ELISA products.
"The combination of DiaSorin and Focus products will create a unique portfolio of specialty products, especially in the clinical area of infectious disease, which will continue to strengthen the leadership of DiaSorin in this segment," said Carlo Rosa, CEO of DiaSorin. "Also, this acquisition offers DiaSorin access to a large number of premier US hospitals that are served today by Focus, a market segment that is strategic for DiaSorin to grow in the future by combining the Focus molecular products with its broad LIAISON product line."
"As a leader in diagnostic products, DiaSorin is well positioned to build on the Focus platform of innovation to deliver continuing value to Focus' employees, customers and patients," said Steve Rusckowski, president and CEO of Quest Diagnostics. "We remain committed to delivering disciplined capital deployment, the fifth element of our five-point strategy. We return the majority of our free cash flow to investors in the form of dividends and share repurchases, and also have been investing in the business through strategically aligned acquisitions."
Related Links:
DiaSorin
Quest Diagnostics
Focus Diagnostics
As a result of the acquisition, DiaSorin will have access to Focus' product lines, including the Simplexa molecular line, the HerpeSelect HSV serology line, and the DxSelect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) assays. This will significantly increase its presence in the growing market of infectious disease molecular testing. DiaSorin will also strengthen its offering in the U.S. market by gaining access to approximately 200 hospitals served today by Focus.
Gaining access to the current Focus customer base in the United States, which consists mainly of large hospitals, will also allow DiaSorin to speed up U.S. market penetration of its LIAISON Immunoassay platform. The company will also leverage its commercial presence worldwide to distribute Focus products in markets in Europe and Asia. Under the terms of the agreement, DiaSorin will pay to Quest Diagnostics USD 300 million in cash for all the tangible and intangible assets of Focus used to develop, manufacture, and distribute its molecular diagnostic products and its traditional immunoassay ELISA products.
"The combination of DiaSorin and Focus products will create a unique portfolio of specialty products, especially in the clinical area of infectious disease, which will continue to strengthen the leadership of DiaSorin in this segment," said Carlo Rosa, CEO of DiaSorin. "Also, this acquisition offers DiaSorin access to a large number of premier US hospitals that are served today by Focus, a market segment that is strategic for DiaSorin to grow in the future by combining the Focus molecular products with its broad LIAISON product line."
"As a leader in diagnostic products, DiaSorin is well positioned to build on the Focus platform of innovation to deliver continuing value to Focus' employees, customers and patients," said Steve Rusckowski, president and CEO of Quest Diagnostics. "We remain committed to delivering disciplined capital deployment, the fifth element of our five-point strategy. We return the majority of our free cash flow to investors in the form of dividends and share repurchases, and also have been investing in the business through strategically aligned acquisitions."
Related Links:
DiaSorin
Quest Diagnostics
Focus Diagnostics
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance